Kenneth Newman, chief medical officer of clinical-stage biopharmaceutical company Verona Pharma, will stand down from his position on 30 April in order to pursue "other opportunities".
Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs, did not immediately name a successor but did not that it had commenced an executive search for a replacement.

Jan-Anders Karlsson, Verona Pharma's chief executive, said, "We thank Ken for his outstanding service and many contributions to the Company. Over the past three years, he has led the acceleration of RPL554's clinical development program into Phase 2b trials and overseen seven successful clinical trials. He played an instrumental role in establishing our US presence and we wish him the best in his future endeavours."

As of 1110 BST, shares had lost 2.29% to 171.00p.

Related share prices
Verona Pharma (VRP) share price